LASER 532-NM ND:YAG PICOSECOND IN TREATMENT OF SOLAR LENTIGO AND EPHELIDES

2020 ◽  
pp. 72-77
Author(s):  
Ha Bui Manh ◽  
Thanh Le Thai Van
Keyword(s):  
Side Effects ◽  
Key Words ◽  
Descriptive Study ◽  
Patient Evaluation ◽  
High Efficacy ◽  
Mild Pain ◽  
Solar Lentigo ◽  
Pre Treatment ◽  
532 Nm

Aims: To evaluate the efficacy, side effects of laser 532-nm Nd:YAG picosecond in treating solar lentigo and ephelides at HCMC hospital of dermato-venereology. Objectives and Method: Prospective - descriptive study. There were 43 patients dealing with solar lentigo and ephelides treated with laser 532-nm Nd:YAG picosecond. Each patient went through 3 treatments with one month interval, three months follow up for delayed side effects and recurrent. Evaluating the treatment by MI, VLCS, self-patient evaluation with 5 grades scale. Evaluating side effects of the treatment by 5 grade Wong-Baker scale. Collected data were analysed with SPSS.20.0. Results: Based on MI at the end of the study, the effectiveness of the treatment gained 81.4% good, 16.3% average and 2.3% bad. Self-patient evaluation revealed 76.7% good, 20.9% average and 2.3% bad. VLCS of post-treatment reduced 7.44 ± 2.14 unit compares with of pre-treatment. Recently after treatment, 100% patients had erythema and mild pain in 5 grade Wong-Baker scale, 20.9% had mild edema, 2.3% had post imflammatory hyperpigmentation (PIH). Two ephelides cases recurred 3 months after treatment (4.6%). Conclusions: Laser 523-nm Nd:YAG picosecond has high efficacy and less side effects in treating solar lentigo and ephelides. Key words: solar lentigo, ephelides, laser 532-nm Nd:YAG picosecond

EFFICACY OF TENOFOVIR IN PATIENTS OF HBV-RELATED CIRRHOSIS

2016 ◽  
pp. 25-29
Author(s):  
Van Huy Tran ◽  
Thi Huyen Thuong Nguyen
Keyword(s):  
Side Effects ◽  
Serum Creatinine ◽  
Key Words ◽  
Tenofovir Disoproxil Fumarate ◽  
Hbv Dna ◽  
Treatment Side Effects ◽  
Background Data ◽  
Key Words Cirrhosis

Background: Data about efficacy of Tenofovir in patients of HBV –related cirrhosis in Vietnam was still limited. This study is aimed at: - evaluating the clinical, biochemical, virological and Child-Pugh score responses 3,6,9 months after Tenofovir therapy; - assessing possible side effects of tenofovir. Patients and methods: 40 patients with HBV-related cirrhosis were enrolled. All has received Tenofovir disoproxil fumarate 300mg/day. Follow-up after 3,6 and 9 months. Results: Anorexia, oedema and ascites were significantly improved after treatment. HBV DNA became undetectable in 92.5%, 94.55 and 100% after 3,6 and 9 months, respectively. Child- Pugh score was improved after treatment (5.94±0.22 after treatment vs 7.47±0.28 before treatment). Side effects were minors (nausea, vomiting). No case of increase in serum creatinine was found. Conclusion: Tenofovir showed effective and safe in patients of HBV-related cirrhosis. Key words: Cirrhosis, tenofovir, HBV. Key words: cirrhosis, tenofovir, HBV

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 223-223 ◽  
Author(s):  
Michael Grövdal ◽  
Rasheed Khan ◽  
Anni Aggerholm ◽  
Petar Antunovic ◽  
Jan Astermark ◽  
...  
Keyword(s):  
Overall Survival ◽  
Side Effects ◽  
High Risk ◽  
Induction Chemotherapy ◽  
Maintenance Treatment ◽  
Methylation Status ◽  
Induction Treatment ◽  
The Mean ◽  
Pre Treatment

Abstract Around 50% of patients with high-risk MDS or MDS-AML may enter CR after induction chemotherapy, but CR duration, as well as overall survival is usually short. To address this clinical problem the Nordic MDS Group designed a prospective multicenter phase II study, which assessed the clinical feasibility and utility of long-term maintenance treatment with azaciditine. Sixty patients with high-risk MDS (IPSS intermediate-2 or high) (n=23) or AML following a previous known MDS (n=37) were enrolled between 2004 and 2006. The mean age was 68 (54–83) and patients should not be eligible for stem cell transplantation. Induction treatment consisted of standard doses of daunorubicin and ara-C. Patients in CR received low dose azacitidine subcutaneously 5/28 days until relapse, unless unacceptable toxicity developed. Methylation status of the P15ink4b (P15), E-cadherine (CDH) and Hypermethylated in Cancer 1 (HIC) gene was analysed at study start, in CR and in some patients during follow up. Last follow up was on August 1 2008, 24 months after the last CR was reported. Twenty-four patients (40%) reached CR and 23 of these started maintenance treatment with azacitidine. The initial dose of azacitidine was 75 mg/m2 but as four of the first five enrolled patients developed grade 4 cytopenia, the starting dose was lowered to 60 mg/m2, and was allowed to be reduced to 45 or 30 mg/m2 to avoid severe cytopenias. The mean dose of azacitidine was 54.3 mg/m2. Azacitidine was well tolerated. In 52% of the cases no side effects at all were reported. The most commonly reported side effect was mild rashes at the injection site (35%). Twenty-two percent developed fever or some kind of infection, mostly mild. Myelosuppression (grade 1–3) was seen in 22% of the cases. As previously reported, the probability of reaching CR was negatively correlated to promoter hypermethylation of CDH (p=0.008) and none of the 6 patients hypermethylated on all 3 genes reached CR (p=0.03) and hence only four patients hypermethylated on other genes than P15 received demethylating therapy. The median CR duration for the azacididine treated group was 13.5 months (2–49+) and median survival time from time of inclusion in the study for the same group was 20 months (4–52+). Four of 23 patients (17%) had a CR exceeding 24 months (32–52+). The two patients hypermethylated on CDH pre-induction had CR durations of only 2 and 5 months respectively. By last follow up 3 patients were still in CR. Of 10 patients without any methylation pre-treatment, all but one maintained this pattern in CR. Of the nine patients with pre treatment methylation of at least one gene, only one remained hypermethylated in CR. This patient had a CR duration of only 5 months. One patient showed development of P15 hypermethylation in the bone marrow sampled at 12 months and relapsed at 15 months. These findings support previous reports on P15 hypermethylation as a marker for minimal residual disease (MRD) and threatening relapse. In the whole group, survival was significantly shorter in patients with CDH methylation (3 vs 9 months, p=0.005), while pre-treatment p15 methylation status did not affect CR duration or overall survival. In conclusion, we show for the first time that maintenance treatment with azacytidine is feasible and associated with a median CR duration of 13.5 months, and very mild side effects. However azacytidine does not seem to prevent relapse in the majority of patients, including those with hypermethylation pre-treatment and/or in CR. Hypermethylation of multiple genes is a strong negative factor for survival, probability of CR, and CR duration. We observe a subset of patients, 17%, with a CR duration of >24 months; but no persistent pattern regarding cytogenetics, methylation or morphology could be identified in this group. The strong negative impact of E-Cadherin methylation, a gene involved in adhesion, warrants further investigation.

scholarly journals Efficacy and Safety of Methotrexate in Combination with Mini Pulse Doses of Methylprednisolone in Severe Alopecia Areata. The Vietnamese Experience

2019 ◽  
Vol 7 (2) ◽  
pp. 200-203
Author(s):  
Anh Tran Thi Van ◽  
Anh Tran Lan ◽  
Minh Ha Anh ◽  
Thuong Nguyen Van ◽  
Phuong Pham Thi Minh ◽  
...  
Keyword(s):  
Side Effects ◽  
Clinical Improvement ◽  
Alopecia Areata ◽  
Hair Growth ◽  
Efficacy And Safety ◽  
National Hospital ◽  
Withdrawal Treatment ◽  
Pulse Dose ◽  
Pre Treatment

BACKGROUND: Treatment of severe alopecia areata remains very difficult, especially in alopecia areata totalis and alopecia areata universalis. Methotrexate is known to be effective in the treatment of severe and chronic autoimmune disorders. OBJECTIVE: To assess the effectiveness and safety of MTX in combination with mini pulse dose of methylprednisolone in the treatment of severe alopecia areata. PATIENTS AND METHODS: The open, uncontrolled study compared pre-treatment and after-treatment. Thirty-eight patients (age 16-64) with severity AA (SALT score > 50 %) visiting National hospital of Dermatology and Venereology from April-2004 to September-2015 were enrolled. All patients received oral methylprednisolone 24mg/day for 3 consecutive days of a week in combination with oral MTX 7,5 mg weekly. This regimen is maintained up to 12 weeks and follow-up until to 6 months. RESULTS: After 6 months, 60.5% of patients show complete hair growth (good response) and 18.4% shows the medium response. There is a significant SALT score reduction: mean baseline SALT score 84.39 ± 17.03 compared to mean post-treatment SALT score 24.19 ± 29.42. Good clinical improvement noted in after 3 months. We do not observe any side- effects related to oral MTX and oral methylprednisolone, and no patients had to withdrawal treatment due to side- effects. CONCLUSION: Combination Methotrexate and mini pulse dose of methylprednisolone are effective and safe in treatment severity alopecia areata.

Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta

2007 ◽  
Vol 14 (2) ◽  
pp. 212-218 ◽  
Author(s):  
R. Farrell ◽  
R. Kapoor ◽  
S. Leary ◽  
P. Rudge ◽  
AJ Thompson ◽  
...  
Keyword(s):  
Side Effects ◽  
Relapse Rate ◽  
Neutralizing Antibodies ◽  
Interferon Beta ◽  
Luciferase Assay ◽  
Published Data ◽  
Serum Samples ◽  
Binding Antibody ◽  
Pre Treatment

Interferon-beta (IFNβ) is a biological therapy which is immunogenic, inducing anti-IFN-β neutralizing antibodies (Nabs) in some subjects. The frequency of Nabs varies depending on IFN-β product and the Nab assay used. Objective Assess frequency of Nabs using novel Luciferase assay, evaluate association with relapses, frequency of side effects and to compare results with published data. Methods Serum samples at 12 and 24 months and a follow up sample were tested for binding and Nabs. Titre >20 NU was considered positive. Charts were reviewed retrospectively for clinical data. Results Out of 327 subjects included, 130 subjects (40%) were binding antibody positive, 89 (27%) were Nab +ve at anytime. Risk at 12 months for being Nab +ve: Avonex 8%, Betaferon 39%, Rebif 33%, P < 10-5; at 24 months 8, 31 and 27% respectively, P = 0.002. Nab titres were highest in Rebif Nab +ve subjects — 50% >320 NU. Annualized relapse rate was 1.53 pre-treatment, after treatment relapse rate was higher in Nab +ve group 0.67 (95% CI 0.38—0.97) versus 0.5 (0.38—0.61) Nab —ve P = 0.04. Nab status at 12 and 24 months was significantly associated with risk of subsequent relapse, risk being greatest in those with highest titres. Side effects were also significantly associated with Nab —ve status. Multiple Sclerosis 2008; 14: 212—218. http://msj.sagepub.com

scholarly journals Nanosecond Q-Switched 1064/532 nm Laser to Treat Hyperpigmentations: A Double Center Retrospective Study

2021 ◽  
Vol 11 (4) ◽  
pp. 708-714
Author(s):  
Steven Paul Nisticò ◽  
Giovanni Cannarozzo ◽  
Eugenio Provenzano ◽  
Federica Tamburi ◽  
Gilda Fazia ◽  
...  
Keyword(s):  
Gold Standard ◽  
Magna Graecia ◽  
Number Of Patients ◽  
Laser Treatments ◽  
Solar Lentigo ◽  
Cosmetic Dermatology ◽  
Minimum Interval ◽  
University Of Rome ◽  
532 Nm

(1) Benign hyperpigmentations are a common problem in cosmetic dermatology. Melasma, solar lentigo, and other acquired hyperpigmentations represent an aesthetic issue for an increasing number of patients. The gold standard in managing this condition is currently 1064/532 nanometers (nm) Q-Switched lasers. This study reports our experience on the use of a Q-switched laser with a nanosecond pulse to treat these conditions. (2) Methods: A total of 96 patients asking for benign hyperpigmentation removal were consecutively enrolled at the Magna Graecia University of Catanzaro and Tor Vergata University of Rome. Treating parameters were the following: 1064 nm with a pulse duration of 6 nanoseconds (ns) for dermic lesions and 532 nm with 6 ns for epidermal ones. Up to five treatments with a minimum interval between laser treatments of thirty days were performed. A follow-up visit three months after the last session assessed patient satisfaction with a Visual Analogue Scale (VAS). Two blinded dermatologists assessed the cosmetic result using a five-point scale comparing pictures before treatment and at follow-up. (3) Results: 96 patients were included; 47 participants were women (49.0%) and 49 men (51.0%). The mean reported age was 50.0 ± 17.3 years. All patients reached a good to complete hyperpigmentation removal at the dermatological evaluation with a mean VAS score of 8.91 ± 1.07. (4) Conclusions: Q Switched 1064/532 nm laser may be considered the gold standard treatment for benign hyperpigmentations. Our results confirm the literature findings on the effectiveness of these devices.

scholarly journals High doses of immunoglobulin g in the therapy for severe forms of myasthenia gravis and Guillain-Barré syndrome

2006 ◽  
Vol 63 (1) ◽  
pp. 37-42
Author(s):  
Dragana Lavrnic ◽  
Marija Romic ◽  
Aleksandra Kacar ◽  
Vidosava Rakocevic-Stojanovic ◽  
Zorica Stevic ◽  
...  
Keyword(s):  
Side Effects ◽  
Myasthenia Gravis ◽  
Immunoglobulin G ◽  
Neurological Diseases ◽  
Ivig Therapy ◽  
Therapeutic Modality ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
High Doses

Background/Aim. High doses of immunoglobulin G (IVIG) have been recognized as a very important therapeutic modality in the treatment of neurological diseases. The aim of this report was to present our experience in the treatment of severe forms of myasthenia gravis (MG) and Guillain-Barr? syndrome (GBS). Methods. We analyzed the efficacy and safety of immunoglobulin G therapy in 53 patients with severe forms of myasthenia gravis, and 27 patients with very severe forms of Guillain-Barr? syndrome. Results. At the end of the follow-up period, a significant improvement was noticed in 47 out of 53 patients with myasthenia gravis ( 88.7%). In the group of 27 patients with severe forms of Guillain-Barr? syndrome an improvement was registered in 19 patients (70.3%). The side effects of this therapy were mostly mild, manifested as headache, myalgia, skin rash, adynamia, and other clinically insignificant effects. No severe side effects were recognized. Conclusions. Our study clearly demonstrated the high efficacy of IVIG therapy in the treatment of severe forms of myastehnia gravis and Guillain-Barr? syndrome.

scholarly journals Antitumor and Immunomodulatory Activities of Peganum harmala Extracts

2013 ◽  
Vol 7 (1) ◽  
pp. 11-20
Author(s):  
Moyassar B. H. Al-shaibani ◽  
Hiba T. H. Al-mafrachi
Keyword(s):  
Side Effects ◽  
Antitumor Activity ◽  
Post Treatment ◽  
Phagocytic Index ◽  
High Efficacy ◽  
Peganum Harmala ◽  
Absolute Count ◽  
Methanolic Extracts ◽  
Antitumor Potential ◽  
Pre Treatment

This study was designed to search the antitumor potential of Peganum harmala methanolic extracts and to evaluate their role in retardation the immunological side effects pre-and post-treatment which were carried out on 30 Albino male mice and included total and absolute count of leucocytes, micronucleus formation and phagocytic index of peritoneal cells. Our study showed that P. harmala derivatives have considerable antitumor activity with high efficacy in immobilization of the immunological side effects evoked following treatment with antitumor drug. In conclusion, P. harmala possess antitumor activity increases with concentrations increasing. Pre-treatment with these extracts exert higher retardation to the side effects than post-treatment.

scholarly journals GAMBARAN HISTOPATOLOGI KARTILAGO SENDI LUTUT TIKUS WISTAR SETELAH PEMBERIAN SIPROFLOKSASIN

2013 ◽  
Vol 1 (1) ◽  
Author(s):  
Poppy Lintong ◽  
Carla Kairupan ◽  
Mulyadi Saul
Keyword(s):  
Side Effects ◽  
Knee Joint ◽  
Key Words ◽  
Wistar Rats ◽  
Descriptive Study ◽  
Knee Joints ◽  
The Matrix ◽  
Per Oral ◽  
Oral Doses ◽  
Fluoroquinolone Group

Abstract: Ciprofloxacin is a kind of antibiotic which belongs to the fluoroquinolone group. It is very effective against microbes, but has several side effects in bones, joints, and tendons, especially for individuals under 18 years. The purpose of this study was to find out the side effects of ciprofloxacin on wistar rats’ knee joints. This was an experimental and descriptive study, using 12 wistar rats as samples, which were grouped in 4 groups: 3 treated, 1 control. The treated groups were given different total daily oral doses of ciprofloxacin (2 mg, 6 mg, and 18 mg) for 14 days. On the 15th day, all the samples were terminated, and their right back knees were examined pathologically, focusing on the knee cartilages. Wistar rats treated with 18 mg ciprofloxacin showed foci of cartilage matrix edema and degradation of chondrocytes. This study concluded that 18 mg doses of ciprofloxacin daily caused destruction of the matrix and chondrocytes of the wistar rats’ knee joint cartilages. Key words: ciprofloxasin, knee joint, matrix edema, chondrocytes’ degradation. Abstrak: Siprofloksasin adalah antibiotik golongan fluorokuinolon yang sangat efektif untuk mengobati infeksi, namun dapat menimbulkan beberapa efek samping, antara lain gangguan pada tulang, sendi, dan tendon, terutama pada yang berusia dibawah 18 tahun. Tujuan penelitian ini untuk mengetahui efek siprofloksasin pada sendi lutut tikus. Penelitian ini bersifat eksperimental deskriptif dengan menggunakan sampel 12 ekor tikus wistar  yang dibagi atas empat kelompok (3 kelompok perlakuan  dan 1 kelompok kontrol). Pada kelompok perlakuan diberikan siprofloksasin per oral dengan  dosis 2mg, 6 mg, dan 18 mg setiap hari  selama 14 hari. (Dosis ini pada manusia dengan berat badan rata  rata 50 kg setara dengan dosis  1000 mg, 3000 mg, dan 9000 mg per hari). Pada hari ke15, tikus kontrol dan perlakuan diterminasi kemudian sendi lutut di eksisi dan dilakukan pemeriksaan histopatologi. Pemeriksaan  histopatologi sendi lutut difokuskan pada jaringan kartilago hialin. Tikus kontrol dan tikus perlakuan dengan pemberian siprofloksasin dosis 2 mg dan 6 mg memperlihatkan jaringan kartilago normal; sedangkan pada tikus perlakuan dengan dosis 18 mg  terlihat fokus-fokus pembengkakan matriks tulang rawan dan degradasi kondrosit. Dari hasil penelitian ini dapat disimpulkan bahwa pemberian siprofloksasin pada tikus wistar dengan dosis 18 mg (setara dengan 9000 mg pada manusia)  per hari selama 14 hari telah menimbulkan kelainan fokal pada kartilago berupa pembengkakan matriks dan degradasi kondrosit. Kata kunci: siprofloksasin, sendi lutut, pembengkakan matriks, degradasi kondrosit.

scholarly journals Outcome of fallopian tube recanalization

1970 ◽  
Vol 3 (1) ◽  
pp. 43-45
Author(s):  
Jageshwor Gautam
Keyword(s):  
Key Words ◽  
Fallopian Tube ◽  
Descriptive Study ◽  
Tubal Occlusion ◽  
Novel Treatment ◽  
Ectopic Pregnancies ◽  
Tubal Surgery

Objective: To find out the fertility outcome of tubal surgery. Method: This was a hospital based descriptive study conducted at Om Hospital, Bharatpur. Forty-one women who were operated in this hospital during the period of 6 years. (Jan 2002- December 2007). Results: Of 41 patients who underwent tuboplasty, 34 (82.9%) cases were available for follow-up. Out of these 34 cases, 14 (41.2%) became pregnant. Among them 9 (64.3%) had viable births, 3 (21.4%) ectopic pregnancies and 2 (14.3%) spontaneous miscarriages. Conclusion: Fallopian tube recanalization has been established as an effective, useful and novel treatment of infertility due to tubal occlusion. Key words: Infertility, fallopian tube, tuboplasty, pregnancy.   doi:10.3126/njog.v3i1.1439 NJOG 2008 May-June; 3(1): 43 - 45

scholarly journals Effects and Side Effects of Pasireotide Treatment in Cushing’s Disease: Experience of a Single Tertiary Center

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A642-A643
Author(s):  
Hande Mefkure Ozkaya ◽  
Serdar Sahin ◽  
Güler Kerimova ◽  
Emre Durcan ◽  
Cem Sulu ◽  
...  
Keyword(s):  
Side Effects ◽  
Cushing’S Disease ◽  
The Body ◽  
Cushing's Disease ◽  
Antidiabetic Medication ◽  
Free Cortisol ◽  
Tertiary Center ◽  
Significant Difference ◽  
Pre Treatment

Abstract Context: Cushing’s disease (CD), when uncontrolled despite surgery, requires medical treatment. In this vein, treatments with long-term effectiveness and safety profiles are needed. We aimed to evaluate the effects and side effects of pasireotide treatment in Cushing’s disease in the real world. Methods: Patients who were followed up for Cushing’s disease and treated with pasireotide between 2001-2019 at Cerrahpaşa Medical Faculty Endocrinology, Metabolism and Diabetes Department were evaluated. Pasireotide efficacy and side effects were evaluated. Results: Thirty-four patients were included in the study. The mean duration of treatment was 24.59 (SD ± 15.21) months. Urinary free cortisol (UFC) decreased in 40.59 % of the patients and normalized in 33.3 %. A total of %71.4 of the patients who were in remission at the 3rd month of the treatment preserved their remission status at last follow-up. A significant difference was found between pre-treatment and final UFC (p = 0.001), but the absence of remission at 3 months did not predict final remission (p = 0.274). ACTH decreased by 9.16 % (SD ± 46.67). A significant difference was found between ACTH levels at 3rd, 6 months, and last control (p = 0.014, 0.017, and 0.017, respectively). Serum cortisol decreased by 13.89 %. A significant difference was found between pre-treatment and 3rd month, pre-treatment and final cortisol (p = 0.034 and 0.013, respectively). The body weight decreased by an average of 5.5 [IQR (0.0-11.5)] kg. Cholecystectomy was performed in 3 patients (9%). The percentage of patients requiring antidiabetic medication increased from 33.3% at diagnosis to 81.8% at the last follow-up visit. A significant difference was found between pre-treatment and 3rd month fasting plasma glucose levels ​​(p = 0.008). HbA1c increased by 17 %. There was a positive correlation between UFC and 3rd month HbA1c. All patients with hyperglycemia were controlled with effective antidiabetic therapy. Conclusion: Pasireotide treatment in CD is effective and safe, remission occurs in the first months of treatment and continues for a long time. Although hyperglycemia is the most common side effect, it is successfully controlled with antidiabetic medication.

Sign in / Sign up

Export Citation Format

Share Document